vs
Side-by-side financial comparison of Foghorn Therapeutics Inc. (FHTX) and NEXPOINT DIVERSIFIED REAL ESTATE TRUST (NXDT). Click either name above to swap in a different company.
NEXPOINT DIVERSIFIED REAL ESTATE TRUST is the larger business by last-quarter revenue ($18.4M vs $9.2M, roughly 2.0× Foghorn Therapeutics Inc.). NEXPOINT DIVERSIFIED REAL ESTATE TRUST runs the higher net margin — -193.1% vs -234.3%, a 41.2% gap on every dollar of revenue. On growth, Foghorn Therapeutics Inc. posted the faster year-over-year revenue change (223.8% vs -29.0%). Over the past eight quarters, Foghorn Therapeutics Inc.'s revenue compounded faster (35.3% CAGR vs 19.9%).
Foghorn Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing novel therapies targeting the chromatin regulatory system to treat various types of cancer and other severe diseases. It advances a diverse pipeline of targeted drug candidates, conducting internal R&D and strategic partnerships to serve global patient populations.
NexPoint Diversified Real Estate Trust is a publicly traded US real estate investment trust. It acquires, manages and optimizes a diversified portfolio covering multifamily housing, industrial facilities, offices and neighborhood retail, generating returns via rental income and long-term property value appreciation.
FHTX vs NXDT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $9.2M | $18.4M |
| Net Profit | $-21.7M | $-35.5M |
| Gross Margin | — | — |
| Operating Margin | -258.2% | -18.8% |
| Net Margin | -234.3% | -193.1% |
| Revenue YoY | 223.8% | -29.0% |
| Net Profit YoY | -11.1% | -291.1% |
| EPS (diluted) | $-0.35 | $-0.73 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $9.2M | $18.4M | ||
| Q3 25 | $8.2M | $17.5M | ||
| Q2 25 | $7.6M | $21.0M | ||
| Q1 25 | $6.0M | $29.1M | ||
| Q4 24 | $2.9M | $25.9M | ||
| Q3 24 | $7.8M | $22.2M | ||
| Q2 24 | $6.9M | $22.3M | ||
| Q1 24 | $5.0M | $12.8M |
| Q4 25 | $-21.7M | $-35.5M | ||
| Q3 25 | $-15.8M | $-13.7M | ||
| Q2 25 | $-17.9M | $-45.3M | ||
| Q1 25 | $-18.8M | $-34.3M | ||
| Q4 24 | $-19.5M | $-9.1M | ||
| Q3 24 | $-19.1M | $-10.0M | ||
| Q2 24 | $-23.0M | $-9.8M | ||
| Q1 24 | $-25.0M | $-22.7M |
| Q4 25 | -258.2% | -18.8% | ||
| Q3 25 | -226.9% | -19.1% | ||
| Q2 25 | -279.2% | -0.6% | ||
| Q1 25 | -385.0% | 19.0% | ||
| Q4 24 | -840.5% | 3.6% | ||
| Q3 24 | -305.5% | -26.8% | ||
| Q2 24 | -386.6% | 2.7% | ||
| Q1 24 | -558.3% | 2.1% |
| Q4 25 | -234.3% | -193.1% | ||
| Q3 25 | -194.4% | -78.4% | ||
| Q2 25 | -237.3% | -215.1% | ||
| Q1 25 | -316.4% | -118.0% | ||
| Q4 24 | -682.9% | -35.0% | ||
| Q3 24 | -244.9% | -45.2% | ||
| Q2 24 | -333.6% | -43.9% | ||
| Q1 24 | -495.4% | -177.3% |
| Q4 25 | $-0.35 | $-0.73 | ||
| Q3 25 | $-0.25 | $-0.29 | ||
| Q2 25 | $-0.28 | $-0.99 | ||
| Q1 25 | $-0.30 | $-0.80 | ||
| Q4 24 | $-0.23 | $-0.20 | ||
| Q3 24 | $-0.31 | $-0.25 | ||
| Q2 24 | $-0.45 | $-0.24 | ||
| Q1 24 | $-0.59 | $-0.59 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $80.9M | $8.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-108.5M | $700.1M |
| Total Assets | $198.1M | $1.1B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $80.9M | $8.2M | ||
| Q3 25 | $89.3M | $5.3M | ||
| Q2 25 | $72.6M | $4.7M | ||
| Q1 25 | $61.0M | $9.5M | ||
| Q4 24 | $55.5M | $8.8M | ||
| Q3 24 | $57.7M | $8.5M | ||
| Q2 24 | $138.9M | $28.4M | ||
| Q1 24 | $79.3M | $20.2M |
| Q4 25 | $-108.5M | $700.1M | ||
| Q3 25 | $-89.7M | $739.0M | ||
| Q2 25 | $-76.7M | $752.7M | ||
| Q1 25 | $-61.7M | $802.7M | ||
| Q4 24 | $-45.5M | $836.5M | ||
| Q3 24 | $-28.3M | $842.9M | ||
| Q2 24 | $-14.3M | $859.1M | ||
| Q1 24 | $-97.5M | $863.0M |
| Q4 25 | $198.1M | $1.1B | ||
| Q3 25 | $205.0M | $1.1B | ||
| Q2 25 | $226.2M | $1.1B | ||
| Q1 25 | $258.7M | $1.2B | ||
| Q4 24 | $284.0M | $1.2B | ||
| Q3 24 | $308.4M | $1.2B | ||
| Q2 24 | $328.6M | $1.2B | ||
| Q1 24 | $255.0M | $1.1B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-22.3M | $9.2M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-22.3M | $9.2M | ||
| Q3 25 | $-18.9M | $835.0K | ||
| Q2 25 | $-21.0M | $75.0K | ||
| Q1 25 | $-24.0M | $7.1M | ||
| Q4 24 | $-24.5M | $-11.7M | ||
| Q3 24 | $-21.0M | $497.0K | ||
| Q2 24 | $-25.5M | $-5.5M | ||
| Q1 24 | $-29.3M | $-2.6M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $-21.0M | — | ||
| Q1 25 | $-24.0M | — | ||
| Q4 24 | $-25.0M | — | ||
| Q3 24 | $-21.3M | — | ||
| Q2 24 | $-25.6M | — | ||
| Q1 24 | $-29.4M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -278.2% | — | ||
| Q1 25 | -403.2% | — | ||
| Q4 24 | -875.3% | — | ||
| Q3 24 | -273.0% | — | ||
| Q2 24 | -371.0% | — | ||
| Q1 24 | -583.1% | — |
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.3% | — | ||
| Q1 25 | 0.5% | — | ||
| Q4 24 | 16.8% | — | ||
| Q3 24 | 4.0% | — | ||
| Q2 24 | 0.2% | — | ||
| Q1 24 | 2.0% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
